Liesbet De Bus1, Wouter Denys2, Julie Catteeuw2, Bram Gadeyne2, Karel Vermeulen3, Jerina Boelens4, Geert Claeys4, Jan J De Waele2, Johan Decruyenaere2, Pieter O Depuydt2,5. 1. Department of Critical Care Medicine, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium. liesbet.debus@ugent.be. 2. Department of Critical Care Medicine, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium. 3. Department of Mathematical Modelling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium. 4. Department of Laboratory Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. 5. Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium.
Abstract
PURPOSE: Antibiotic de-escalation is promoted to limit prolonged exposure to broad-spectrum antibiotics, but proof that it prevents the emergence of resistance is lacking. We evaluated determinants of antibiotic de-escalation in an attempt to assess whether the latter is associated with a lower emergence of antimicrobial resistance. METHODS: Antibiotic treatments, starting with empirical beta-lactam prescriptions, were prospectively documented during 2013 and 2014 in a tertiary intensive care unit (ICU) and categorized as continuation, de-escalation or escalation of the empirical antimicrobial treatment. Determinants of the de-escalation or escalation treatments were identified by multivariate logistic regression; the continuation category was used as the reference group. Using systematically collected diagnostic and surveillance cultures, we estimated the cumulative incidence of antimicrobial resistance following de-escalation or continuation of therapy, with adjustment for ICU discharge and death as competing risks. RESULTS: Of 478 anti-pseudomonal antibiotic prescriptions, 42 (9 %) were classified as escalation of the antimicrobial treatment and 121 (25 %) were classified as de-escalation, mainly through replacement of the originally prescribed antibiotics with those having a narrower spectrum. In multivariate analysis, de-escalation was associated with the identification of etiologic pathogens (p < 0.001). The duration of the antibiotic course in the ICU in de-escalated versus continued prescriptions was 8 (range 6-10) versus 5 (range 4-7) days, respectively (p < 0.001). Mortality did not differ between patients in the de-escalation and continuation categories. The cumulative incidence estimates of the emergence of resistance to the initial beta-lactam antibiotic on day 14 were 30.6 and 23.5 % for de-escalation and continuation, respectively (p = 0.22). For the selection of multi-drug resistant pathogens, these values were 23.5 (de-escalation) and 18.6 % (continuation) respectively (p = 0.35). CONCLUSION: The emergence of antibiotic-resistant bacteria after exposure to anti-pseudomonal beta-lactam antibiotics was not lower following de-escalation.
PURPOSE: Antibiotic de-escalation is promoted to limit prolonged exposure to broad-spectrum antibiotics, but proof that it prevents the emergence of resistance is lacking. We evaluated determinants of antibiotic de-escalation in an attempt to assess whether the latter is associated with a lower emergence of antimicrobial resistance. METHODS: Antibiotic treatments, starting with empirical beta-lactam prescriptions, were prospectively documented during 2013 and 2014 in a tertiary intensive care unit (ICU) and categorized as continuation, de-escalation or escalation of the empirical antimicrobial treatment. Determinants of the de-escalation or escalation treatments were identified by multivariate logistic regression; the continuation category was used as the reference group. Using systematically collected diagnostic and surveillance cultures, we estimated the cumulative incidence of antimicrobial resistance following de-escalation or continuation of therapy, with adjustment for ICU discharge and death as competing risks. RESULTS: Of 478 anti-pseudomonal antibiotic prescriptions, 42 (9 %) were classified as escalation of the antimicrobial treatment and 121 (25 %) were classified as de-escalation, mainly through replacement of the originally prescribed antibiotics with those having a narrower spectrum. In multivariate analysis, de-escalation was associated with the identification of etiologic pathogens (p < 0.001). The duration of the antibiotic course in the ICU in de-escalated versus continued prescriptions was 8 (range 6-10) versus 5 (range 4-7) days, respectively (p < 0.001). Mortality did not differ between patients in the de-escalation and continuation categories. The cumulative incidence estimates of the emergence of resistance to the initial beta-lactam antibiotic on day 14 were 30.6 and 23.5 % for de-escalation and continuation, respectively (p = 0.22). For the selection of multi-drug resistant pathogens, these values were 23.5 (de-escalation) and 18.6 % (continuation) respectively (p = 0.35). CONCLUSION: The emergence of antibiotic-resistant bacteria after exposure to anti-pseudomonal beta-lactam antibiotics was not lower following de-escalation.
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: Jan J De Waele; Mariska Ravyts; Pieter Depuydt; Stijn I Blot; Johan Decruyenaere; Dirk Vogelaers Journal: J Crit Care Date: 2010-01-15 Impact factor: 3.425
Authors: Liesbet De Bus; Lies Saerens; Bram Gadeyne; Jerina Boelens; Geert Claeys; Jan J De Waele; Dominique D Benoit; Johan Decruyenaere; Pieter O Depuydt Journal: Crit Care Date: 2014-07-15 Impact factor: 9.097
Authors: Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier Journal: Intensive Care Med Date: 2019-01-18 Impact factor: 17.440
Authors: Alexis Tabah; Matteo Bassetti; Marin H Kollef; Jean-Ralph Zahar; José-Artur Paiva; Jean-Francois Timsit; Jason A Roberts; Jeroen Schouten; Helen Giamarellou; Jordi Rello; Jan De Waele; Andrew F Shorr; Marc Leone; Garyphallia Poulakou; Pieter Depuydt; Jose Garnacho-Montero Journal: Intensive Care Med Date: 2019-11-28 Impact factor: 17.440
Authors: Luis Eduardo López-Cortés; Clara Rosso-Fernández; María Núñez-Núñez; Lucía Lavín-Alconero; José Bravo-Ferrer; Ángel Barriga; Mercedes Delgado; Carmen Lupión; Pilar Retamar; Jesús Rodríguez-Baño Journal: BMJ Open Date: 2017-06-09 Impact factor: 2.692
Authors: Omar Nunez Lopez; Janos Cambiaso-Daniel; Ludwik K Branski; William B Norbury; David N Herndon Journal: Ther Clin Risk Manag Date: 2017-08-29 Impact factor: 2.423
Authors: Jenna Wiens; Graham M Snyder; Samuel Finlayson; Monica V Mahoney; Leo Anthony Celi Journal: Open Forum Infect Dis Date: 2017-12-19 Impact factor: 3.835